Edition:
United Kingdom

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.86USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
141,107
52-wk High
$4.81
52-wk Low
$2.24

Latest Key Developments (Source: Significant Developments)

Ophthotech Q3 earnings per share $5.25
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ophthotech Corp ::Ophthotech reports third quarter 2017 financial and operating results.Q3 earnings per share $5.25.Q3 earnings per share view $2.67 -- Thomson Reuters I/B/E/S.Ophthotech Corp - ‍collaboration revenue was $206.7 million for quarter ended September 30, 2017, compared to $1.7 million for same period in 2016​.Ophthotech Corp - ‍as of September 30, 2017, company had $180.2 million in cash and cash equivalents​.Ophthotech Corp - ‍expects a 2017 year end cash balance of between $155 million and $165 million​.  Full Article

Ophthotech says Fovista phase 3 trial did not meet primary endpoint
Monday, 12 Dec 2016 

Ophthotech Corp : pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials . addition of Fovista to monthly Lucentis regimen did not result in benefit as measured by mean change in visual acuity at 12 month time point . based on preliminary analysis of safety data, Fovista and Lucentis monotherapy were generally well tolerated after one year of treatmen .Ophthotech announces results from pivotal phase 3 trials of Fovista in wet age-related macular degeneration.  Full Article

Ophthotech Q2 loss per share $0.85
Wednesday, 3 Aug 2016 

Ophthotech Corp : Q2 loss per share $0.85 . Q2 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S .Says collaboration revenue was $28.2 million for quarter ended June 30, 2016, compared to $1.6 million for same period in 2015.  Full Article

Ophthotech says achieved $30 mln enrollment milestone from Novartis Pharma
Monday, 20 Jun 2016 

Ophthotech : Says has achieved a $30 million enrollment milestone from novartis pharma ag as part of ex-us licensing . Expects to announce initial, topline data from two studies in q4 of this year . Says expects to announce initial, topline data from two studies in q4 of this year .Completes patient recruitment in phase 3 trial of Fovista® anti-pdgf therapy in combination with eylea® or avastin® in wet age-related macular degeneration.  Full Article

BRIEF-Ophthotech Announces Election Of Jane Pritchett Henderson, CFO And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

* OPHTHOTECH ANNOUNCES ELECTION OF JANE PRITCHETT HENDERSON, CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT AT VOYAGER THERAPEUTICS, TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: